GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ITeos Therapeutics Inc (NAS:ITOS) » Definitions » 3-Year EPS without NRI Growth Rate

ITeos Therapeutics (ITeos Therapeutics) 3-Year EPS without NRI Growth Rate : -3.00% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is ITeos Therapeutics 3-Year EPS without NRI Growth Rate?

ITeos Therapeutics's EPS without NRI for the three months ended in Dec. 2023 was $-0.85.

During the past 12 months, ITeos Therapeutics's average EPS without NRI Growth Rate was -223.00% per year. During the past 3 years, the average EPS without NRI Growth Rate was -3.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 6 years, the highest 3-Year average EPS without NRI Growth Rate of ITeos Therapeutics was -3.00% per year. The lowest was -3.00% per year. And the median was -3.00% per year.


Competitive Comparison of ITeos Therapeutics's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, ITeos Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ITeos Therapeutics's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ITeos Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where ITeos Therapeutics's 3-Year EPS without NRI Growth Rate falls into.



ITeos Therapeutics 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


ITeos Therapeutics  (NAS:ITOS) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


ITeos Therapeutics 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of ITeos Therapeutics's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


ITeos Therapeutics (ITeos Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
321 Arsenal Street, Watertown, MA, USA, 02472
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
Executives
Matthew Gall officer: Chief Financial Officer C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Aaron I. Davis other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Joseph Lewis other: See remarks PO BOX N7776, LYFORD BAHAMAS
Boxer Asset Management Inc. other: See remarks CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Boxer Capital, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
David Hallal director C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Michel Detheux director, officer: Chief Executive Officer C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Yvonne Mcgrath officer: VP, Research and Development C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Joanne Jenkins Lager officer: Chief Medical Officer C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Ubs Oncology Impact Fund L.p. other: X* 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2018, L.p. 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Detlev Biniszkiewicz director C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Tony W Ho director CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Robert Iannone director 300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950

ITeos Therapeutics (ITeos Therapeutics) Headlines

From GuruFocus

iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-03-2023

iTeos Provides Business Updates and Clinical Development Plans for 2023

By Stock market mentor Stock market mentor 01-09-2023

iTeos to Present at the Cowen 42nd Annual Health Care Conference

By GuruFocusNews GuruFocusNews 03-01-2022

iTeos to Present at the 40th Annual J.P. Morgan Healthcare Conference

By GuruFocusNews GuruFocusNews 01-03-2022